NEW YORK, October 23, 2017 /PRNewswire/ --
If you want a Stock Review on BMY, JNJ, LLY, or MRK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. The Pharmaceutical industry is the part of the Healthcare sector that deals with medications. Its main goal is to provide drugs that prevent infections, maintain health, and cure diseases. For today, DailyStockTracker.com has issued research reports on four major players in the Drug Manufacturers space: Bristol-Myers Squibb Co. (NYSE: BMY), Johnson & Johnson (NYSE: JNJ), Eli Lilly and Co. (NYSE: LLY), and Merck & Co. Inc. (NYSE: MRK). Daily Stock Tracker published free research reports on these stocks today at:

http://dailystocktracker.com/register/

Bristol-Myers Squibb

New York headquartered Bristol-Myers Squibb Co.'s stock saw a slight correction of 0.39%, finishing last Friday's trading session at $64.42. A total volume of 5.23 million shares was traded. The Company's shares have gained 1.72% in the last month, 15.86% over the previous three months, and 10.23% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.61% and 14.10%, respectively. Additionally, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have a Relative Strength Index (RSI) of 57.52.

On October 16(th) , 2017, research firm Jefferies downgraded the Company's stock rating from 'Buy' to 'Hold'.

On October 16(th) , 2017, Bristol-Myers Squibb announced that the US FDA has accepted for priority review its supplemental Biologics License Application for Opdivo (nivolumab) to treat patients with melanoma, who are at high risk of disease recurrence following complete surgical resection. The FDA also previously granted Breakthrough Therapy Designation for this application, which is the seventh indication for which Opdivo has received this designation. See our free and comprehensive research report on BMY at:

http://dailystocktracker.com/registration/?symbol=BMY

Johnson & Johnson

Shares in New Brunswick, New Jersey-based Johnson & Johnson ended at $142.40, up 0.25% from the last trading session. The stock recorded a trading volume of 5.63 million shares, which was above its three months average volume of 5.37 million shares. The Company's shares have advanced 8.08% in the past month, 7.06% over the previous three months, and 23.60% since the start of this year. The stock is trading 6.82% and 11.85% above its 50-day and 200-day moving averages, respectively. Moreover, shares of the Company have an RSI of 78.07.

On October 18(th) , 2017, research firm Stifel reiterated its 'Hold' rating on the Company's stock with an increase of the target price from $140 a share to $142 a share.

On October 19(th) , 2017, Johnson & Johnson announced that its Board of Directors has declared a cash dividend for Q4 2017 of $0.84 per share on the Company's common stock. The dividend is payable on December 12(th) , 2017, to shareholders of record at the close of business on November 28(th) , 2017. The ex-dividend date is November 27(th) , 2017. JNJ free research report is just a click away at: